Table 7. Treatment-emergent adverse events.

	IR	MRT-F1	MRT-F2	MP	SCT-F1	SCT-F2
Fasting, n (%)	20	21	20	19	21	21
All adverse events	2 (25.0)	4 (19.0)	5 (25.0)	4 (21.1)	2 (9.5)	2 (9.5)
Serious adverse events	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to discontinuation	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Most commona
Headache	2 (10.0)	1 (4.8)	1 (5.0)	2 (10.5)	1 (4.8)	0 (0.0)
Vomiting	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.3)	1 (4.8)	0 (0.0)
Nonfasting, n (%)	21	20	20	21	22	22
All adverse events	5 (23.8)	4 (20.0)	1 (5.0)	1 (4.8)	4 (18.2)	2 (9.1)
Serious adverse events	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to discontinuation	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.8)	0 (0.0)	0 (0.0)
Most commona
Headache	3 (14.3)	1 (5.0)	0 (0.0)	0 (0.0)	1 (4.5)	1 (4.5)
Dermatitis contact	0 (0.0)	1 (5.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Upper respiratory tract infection	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)

IR = immediate release; MP = multiparticulate; MRT-F = matrix tablet; SCT-F = swellable core tablet. ^aOccurring in ≥ 2 patients.